CRMD | tickerfilter.com

Fundamental analysis

20%

Profitability 0%

Dept financing 6%

Liquidity 75%

Performance 30%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

15.87%

1 Month

-36.72%

3 Months

-39.32%

6 Months

-31.62%

1 Year

42.95%

2 Year

45.71%

Key data

Stock price

$6.79

P/E Ratio

0.00

DAY RANGE

$6.69 - $7.71

EPS

-$0.30

52 WEEK RANGE

$3.61 - $13.85

52 WEEK CHANGE

$28.60

MARKET CAP

476.860 M

YIELD

N/A

SHARES OUTSTANDING

55.860 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-08-2025

BETA

2.14

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,808,929

AVERAGE 30 VOLUME

$2,211,471

Company detail

CEO: Joseph Todisco
Region: US
Website: cormedix.com
Employees: 30
IPO year: 2010

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

CorMedix Inc. focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings.

CRMD - CorMedix Inc.